Eli Lilly's Open Source Approach To Early Stage Research

Eli Lilly, which like many big pharmas faces patent expiries and an uncertain late-stage pipeline, has worked to improve ties with the venture and academic communities to help spur access to early-stage and less expensive assets. Since 2009 it has operated a web portal that allows outside researchers to submit compounds for interrogation using Eli Lilly’s drug-discovery assays.

Eli Lilly & Co., which like many big pharmas faces patent expiries and an uncertain late-stage pipeline, has worked to improve ties with the venture and academic communities to help spur access to early-stage and less expensive assets. The pharma's latest attempt to woo academics is perhaps not as flashy as the methods of competitors such as Pfizer Inc., Sanofi, and GlaxoSmithKline PLC – each of which is putting considerable resources behind gaining access to top-notch academic researchers worldwide. But Lilly plans to make up for that in simplicity and sheer volume. ( See "Back To School: Big Pharmas Test New Models For Tapping Academia," IN VIVO , February 2011 Also see "Back To School: Big Pharmas Test New Models For Tapping Academia " - In Vivo, 1 February, 2011..)

Since 2009 Lilly has operated a web portal that allows outside researchers to submit compounds for interrogation using Eli Lilly's...

More from Archive

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.